Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous vs Cyclical Yasmin in PCOS
NCT03819140Phase 4Completed
- Sponsor
- University of California, San Francisco
- Start
- Apr 2019
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of drospirenone in polycystic ovary syndrome (PCOS) (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Change in Biochemical Hyperandrogenism at 6 months. Started Apr 2019; status: completed.
02
Drugs
drospirenone
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on NCT03819140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03819140.